Ensitrelvir
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Ensitrelvir
- Molecular weight
- 531.89
- Structure (SMILES)
- Cn1cnc(Cn2c(=O)[nH]/c(=N\c3cc4cn(C)nc4cc3Cl)n(Cc3cc(F)c(F)cc3F)c2=O)n1
- ensitrelvir
- Ensitrelvir
- Ensitrelvir [INN]
- Ensitrelvir [MI]
- Ensitrelvir [USAN]
- Ensitrelvir [WHO-DD]
- ensitrelvir inn
- ensitrelvir mi
- ensitrelvir usan
- ensitrelvir who dd
- s 217622
- S-217622
- Shionogi Protease Inhibitor (S-217622)
- ATC classification codes
- J05AE16
Sources for recorded values
- CAS registry numbers
- 2647530-73-0
- ChEMBL ID
- CHEMBL5183847
- InChIKey
- QMPBBNUOBOFBFS-UHFFFAOYSA-N
- PubChem compound IDs
- 162533924
- RxNorm IDs (RxCUI)
- 2745988
- FDA ingredient codes (UNII)
- PX665RAA3H
- Status
- opinion
- Status date
- 23 Jun 2026
- Approved indications
- Treatment of coronavirus disease 2019 (COVID-19).
- Product number
- EMEA/H/C/006063
- Authorisation holder
- Shionogi B.V.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- COVID-19 virus infection
European medicines record
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- ensitrelvir
- Type
- Synthetic organic
- Drug name stem
- -vir
- Approval recorded by Guide to Pharmacology
- Yes
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Virus Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000763
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005108
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT05041907
- NCT05605093
- NCT05897541
- NCT05305547
- NCT05363215
- NCT05409911
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 1
- Polar surface area
- 120.68
- Calculated partition coefficient (ALogP)
- 1.75
- Calculated partition coefficient (XLogP)
- 2.5
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 5
- Heavy atoms
- 37
- Molecular formula
- C22H17ClF3N9O2
- Monoisotopic mass
- 531.1145830
- Natural product
- No
- 59630-711
- Recorded assays
- 102
- Active assays
- 36
Active assay types
- Confirmatory
Oral bioavailability
- Median
- 96.7
- Mean
- 96.7
- Minimum
- 96.7
- Maximum
- 96.7
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (8)
- A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants
- A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
- A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
- A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
- Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
- Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
- Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
In development for (5)
- COVID-19 Phase 3
- Kidney disorder Phase 1
- Liver disorder Phase 1
- Severe acute respiratory syndrome Phase 3
- Viral infectious disease Phase 3